The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial.

Geroscience · 2023 · PMC9735188 · PMID 36482258

Europe PMC DOI

hedged sentence

0.0790

closest p · 1.6× alpha

0.0790

boldest claim

The sentences

showed a trendp = 0.079so close (0.05 < p ≤ 0.1)

Participants in the 600 mg and 900 mg NMN-treated group walked a significantly longer distance at both 30-day and 60-day compared to baseline (all p < 0.05), while the 300 mg NMN group showed a trend at day 60 ( p = 0.079).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.